INVICTUS: A phase III, interventional, double-blind, placebo-controlled study to assess the safety and efficacy of ripretinib as ≥ 4th-line therapy in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior anticancer therapies (NCT03353753)

M. von Mehren; César Serrano; Sebastian Bauer; Hans Gelderblom; Suzanne George; Michael Heinrich; Patrick Schöffski; John Zalcberg; Ping Chi; Robin L. Jones; Peter Reichardt; Steven Attia; Gina Z. D'Amato; Julie Meade; K. Shi; Rodrigo Ruiz-Soto; J.-Y. Blay

doi:10.1093/annonc/mdz394.087

Back

INVICTUS: A phase III, interventional, double-blind, placebo-controlled study to assess the safety and efficacy of ripretinib as ≥ 4th-line therapy in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior anticancer therapies (NCT03353753)

Journal article

Peer reviewed

INVICTUS: A phase III, interventional, double-blind, placebo-controlled study to assess the safety and efficacy of ripretinib as ≥ 4th-line therapy in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior anticancer therapies (NCT03353753)

M. von Mehren, César Serrano, Sebastian Bauer, Hans Gelderblom, Suzanne George, Michael Heinrich, Patrick Schöffski, John Zalcberg, Ping Chi, Robin L. Jones, …

Annals of Oncology, Vol.30

2019

DOI: https://doi.org/10.1093/annonc/mdz394.087

Files and links (4)

url

https://lens.org/005-663-488-777-250View

url

https://academic.oup.com/annonc/article/30/Supplement_5/mdz394.087/5578362View

url

https://www.annalsofoncology.org/article/S0923-7534(19)60447-3/fulltextView

url

https://www.sciencedirect.com/science/article/pii/S0923753419604473View

Metrics

1 Record Views

See more details

Details

Title: INVICTUS: A phase III, interventional, double-blind, placebo-controlled study to assess the safety and efficacy of ripretinib as ≥ 4th-line therapy in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior anticancer therapies (NCT03353753)
Creators: M. von Mehren - Fox Chase Cancer Center
César Serrano - Vall d'Hebron Hospital Universitari
Sebastian Bauer - Sarcoma Center, University Hospital Essen West German Cancer Center, Essen, Germany
Hans Gelderblom - Centrum
Suzanne George - Dana–Farber Cancer Institute
Michael Heinrich - Hematology/Medical Oncology, OHSU Knight Cancer Institute, Portland, OR, USA
Patrick Schöffski - KU Leuven
John Zalcberg - Alfred Health
Ping Chi - Memorial Sloan Kettering Cancer Center
Robin L. Jones - Sarcoma Unit, Royal Marsden and Institute of Cancer Research, London, UK
Peter Reichardt - Helios Hospital Berlin-Buch
Steven Attia - Winneshiek Medical Center
Gina Z. D'Amato - Sylvester Comprehensive Cancer Center
Julie Meade - Deciphera Pharmaceuticals
K. Shi - Deciphera Pharmaceuticals
Rodrigo Ruiz-Soto - Deciphera Pharmaceuticals
J.-Y. Blay - Centre Léon Bérard
Publication Details: Annals of Oncology, Vol.30
Publisher: Elsevier BV; United Kingdom
Academic Unit: Miller School of Medicine; UMMG Department of Medicine
Resource Type: Journal article
Record Identifier: 991031733618102976